Product Images Alendronate
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 8 images provide visual information about the product associated with Alendronate NDC 68071-4017 by Nucare Pharmaceuticals,inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
pdp - 68071 4017 04 a148
The text appears to be a label of a medication product named "Alendronate Sodium 35mg" along with its various details such as NDC numbers, lot numbers, RX number, Exp dates, and the manufacturer's name and address. It also includes warnings such as "KEEP OUT OF REACH OF CHILDREN" and storage information "STORE AT CONTROLLED TEMPERATURE 58-86 °F".*
Chemical Structure - alendronate 01
Figure 1 - alendronate 02
This appears to be a chart or table displaying cumulative incidence percentages over time (measured in months) for a placebo and a medication called Alendronate Sodium. However, without more information or context it is difficult to determine what specific condition or disease these percentages are related to.*
Figure 2 - alendronate 03
Figure 3 - alendronate 04
This appears to be a graph showing the mean percent change in bone mineral density (BMD) for a study comparing alendronate sodium 10mg to a placebo in a US and multinational cohort over 36 months. The graph shows BMD changes from baseline at 0, 12, 24, and 36 months for both the treatment group and the placebo group.*
Figure 4 - alendronate 05
This appears to be a table showing the mean percentage change with standard error (SE) in bone mineral density (BMD) at various locations during a 2-year and 3-year study comparing the effects of Alendronate Sodium 5mg/day to placebo. The locations measured include the lumbar spine, femoral trochanter, total hip, and neck of the femur.*
Figure 5 - alendronate 06
Figure 6 - alendronate 07
This appears to be a chart showing the mean percent change from baseline in serum alkaline phosphatase levels over time for different treatments in a study. The treatments listed are a placebo, etidronate 400 mg/day, and alendronate sodium 40 mg/day in both a multinational and U.S. study. The chart shows a decrease in alkaline phosphatase levels over time for all treatments except for a sharp and significant decrease for the placebo treatment.*
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.